On June 3, BioVaxys Technology Corp. (OTC:BVAXF) issued a comprehensive corporate update, detailing its strategic initiatives. BioVaxys is focusing on strategic initiatives, such as integrating assets acquired from IMV Inc. in February 2024, out-licensing its DPX platform, and restarting clinical studies, notably DPX-surMAGE for advanced bladder cancer. The company is also expanding its pipeline through collaborations and reducing risks by seeking co-development partners for late-stage clinical programs.
A scientist in a biopharmaceutical laboratory examining the development of a product candidate intended to treat a central nervous system disease.
These efforts are expected to enhance BioVaxys’s market position in cancer immunotherapy. BioVaxys’s late-stage pipeline includes MVP-S, which is currently in phase 2b clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma/DLBCL and platinum-resistant ovarian cancer. Results from a phase 1b/2 study of MVP-S in combination with low-dose cyclophosphamide in patients with recurrent ovarian cancer showed that this combination was well-tolerated and generated an overall response rate of 21% and a disease control rate of 63%.
In a phase 2b study, MVP-S, plus the immunotherapy drug Keytruda (pembrolizumab), also showed promising results in the treatment of patients with relapsed/refractory DLBCL, where 3/6 patients in the study arm experienced confirmed complete responses.
BioVaxys Technology Corp. is a clinical-stage biotechnology company that develops viral and oncology vaccine platforms and immuno-diagnostics.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center